ABX-CRO and VirtualScopics Collaborate to Enhance Global Molecular Imaging Offerings
ROCHESTER, NY - September 7, 2010 - VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, today announced it has entered into a scientific collaboration, specific to molecular imaging, with ABX-CRO, a Dresden, Germany based full-service contract research organization. The collaboration joins two of the scientific pioneers in the use of advanced imaging for the clinical study of drugs and medical devices....
This partnership will provide pharmaceutical customers with an integrated service offering by leveraging the combined knowledge and experience of both VirtualScopics and ABX-CRO in the area of functional imaging, especially, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). The companies' complementary expertise in imaging analysis and administration of radiopharmaceuticals offers turn-key solutions to customers seeking to capitalize on molecular imaging's ability to quantitatively assess pharmacokinetics and metabolism.
"This collaboration of two of the leaders in the use of molecular imaging in clinical trials will allow each company's customers to source best in class service offerings on a global basis," said VirtualScopics President and Chief Executive Officer, Jeff Markin. He continued, "The coupling of VirtualScopics' robust image acquisition and analysis package with ABX-CRO's expertise with new and evolving tracers will provide a unique and unparalleled solution with regard to the use of functional imaging in drug and medical device development."
ABX-DIRECT white paper (PDF).
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions.
ABX-CRO’s distinctive research solutions for imaging endpoints:
• Global Reach: Africa / Australia / America / Europe / Japan
• Multicentre Molecular Imaging (PET / SPECT / MRI)
• Global Radiopharmacy Set-up
• Radiopharmaceutical satellite distribution
• Quantitative camera & periphery QA (PET / SPECT / MR)
• Advanced Molecular Imaging CoreLab
• Integrated Imaging solutions for phase I–III trials